Optics News

Eyenovia’s phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company’s Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology.

According to a new report from the National Academies of Sciences, Engineering and Medicine, more consistent international data are necessary to fully understand myopia and its underlying mechanisms.

Patients with amblyopia who were treated with the CureSight eye-tracking system achieved greater improvement in visual acuity at week 16 vs. those treated with patching, according to a study published in American Journal of Ophthalmology.

LENZ Therapeutics has submitted a new drug application to the FDA for LNZ100, a preservative-free, once-daily aceclidine-based ophthalmic solution designed to treat presbyopia, the company announced in a press release.

The progression of myopia among school-aged children in China appeared to primarily affect changes in inner retinal thickness over the course of 1 year, according to research.

PHILADELPHIA — In this video, Michael Fisher, MD, discusses the results of a natural history study he presented at the International Symposium on Pediatric Neuro-Oncology.

Digital health company Luminopia Inc. announced real-world data from the Patients Using Prescription Luminopia Registry, which demonstrated the efficacy of its binocular, virtual reality-based medical device for children with amblyopia.

The FDA cleared the LFR-260, a light field powered subjective tele-refractor, Evolution Optiks announced in a press release.